Deoxycarnitine
Introduction
Section titled “Introduction”Deoxycarnitine is a naturally occurring metabolite involved in the broader carnitine pathway, which plays a crucial role in cellular energy metabolism. Carnitine and its derivatives are essential for transporting long-chain fatty acids from the cytosol into the mitochondria, where they undergo beta-oxidation to produce energy. Deoxycarnitine is often considered a precursor or an intermediate within this vital metabolic network.
Biological Basis
Section titled “Biological Basis”The field of metabolomics, which involves the comprehensive measurement of endogenous metabolites in biological fluids like human serum, has advanced our understanding of these compounds. Genetic variations that influence the homeostasis of key metabolites, including those involved in lipid and amino acid metabolism, can provide insights into an individual’s physiological state.[1]As a component of the carnitine system, deoxycarnitine’s levels are intrinsically linked to the efficiency of fatty acid processing, a fundamental biological process.
Clinical Relevance
Section titled “Clinical Relevance”Research utilizing genome-wide association studies (GWAS) has begun to identify genetic variants associated with profiles of various metabolites, including those related to lipid metabolism. [1]Given its connection to carnitine, variations in deoxycarnitine levels may be relevant to metabolic disorders, cardiovascular health, and conditions associated with altered fatty acid oxidation. Studies have explored genetic loci influencing lipid concentrations, such as low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, which are key indicators of cardiovascular risk.[2] For instance, common genetic variants in genes like HMGCR have been linked to LDL-cholesterol levels and can affect alternative splicing, impacting the regulation of cholesterol synthesis. [3]While not directly about deoxycarnitine, this illustrates how genetic factors influence metabolic pathways with clinical consequences. The identification of metabolites as biomarkers for cardiovascular disease and dyslipidemia further highlights their potential clinical utility.[4]
Social Importance
Section titled “Social Importance”Understanding the genetic and metabolic factors influencing deoxycarnitine levels and its pathway has significant social importance. By providing a functional readout of the physiological state, metabolomics, combined with genetic studies, can illuminate the underlying mechanisms of complex traits and diseases.[1]This knowledge can contribute to the development of personalized medicine approaches, enabling earlier risk prediction, more targeted preventative strategies, and novel therapeutic interventions for metabolic and cardiovascular conditions. Research in this area also opens new avenues for exploring the interplay between genetics, environment, and health outcomes, potentially improving public health strategies.[4]
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Research into the genetic determinants of metabolites like deoxycarnitine faces several methodological and statistical challenges that influence the robustness and interpretation of findings. Many studies, including those contributing to our understanding of related metabolic traits, are susceptible to false negative results due to moderate cohort sizes, which may lack sufficient statistical power to detect subtle genetic effects.[5] Conversely, a fundamental challenge in genome-wide association studies (GWAS) is the prioritization of significant associations, as many p-values in exploratory analyses may represent false positive findings without independent replication. [5] The gold standard of replication in independent populations is often difficult to achieve, and when attempted, only a fraction of initial associations are consistently validated, potentially due to differences in study cohorts or initial false positive discoveries. [5] Furthermore, inconsistencies in statistical approaches, such as variations in covariate adjustments (e.g., inclusion of age2) or the exclusion criteria for outliers across different cohorts, can introduce heterogeneity and complicate meta-analyses. [2]
The reliance on imputation methods to infer missing genotypes, while expanding genomic coverage, introduces an estimated error rate ranging from 1.46% to 2.14% per allele, which could impact the accuracy of genotype-phenotype associations for metabolites like deoxycarnitine.[6] Additionally, the assumption of an additive model of inheritance in many analyses might oversimplify complex genetic architectures, potentially overlooking non-additive effects or gene-gene interactions that contribute to metabolite variation. [2]Some analyses focused exclusively on multivariable models, which, while useful, might inadvertently miss important bivariate associations between single nucleotide polymorphisms and metabolite levels.[7]These factors collectively highlight the need for rigorous statistical validation and consistent methodological application across studies to enhance the reliability of genetic discoveries for deoxycarnitine.
Population Specificity and Generalizability
Section titled “Population Specificity and Generalizability”A significant limitation across many genetic studies of metabolic traits is the predominant focus on populations of European ancestry, which restricts the generalizability of findings to broader, ethnically diverse populations. For instance, several discovery and replication cohorts for lipid-related traits were composed entirely of individuals of self-reported European descent, or non-European individuals were explicitly excluded from analyses. [2] This lack of ethnic diversity means that genetic associations identified in these populations may not be directly transferable or have the same effect sizes in other ancestral groups, such as those represented in multiethnic samples from Singapore. [2]Consequently, the genetic architecture influencing deoxycarnitine levels could vary substantially across different ancestries, necessitating specific investigations in diverse populations to fully understand its global genetic landscape.
Beyond ancestry, cohort-specific biases can further limit generalizability. Studies predominantly involving middle-aged to elderly participants, such as the Framingham Heart Study, may introduce a survival bias if DNA samples were collected at later examinations, meaning the findings might not be representative of younger individuals or those who did not survive to later life stages. [5]The unique environmental and lifestyle factors inherent to specific geographic cohorts can also modulate genetic effects, making it uncertain how results from one population would apply to others with different demographic compositions or exposures.[7]Therefore, while providing valuable insights into specific populations, these studies underscore the critical need for broader and more diverse sampling to ensure that genetic associations for deoxycarnitine are robust and universally applicable.
Phenotypic Definition and Environmental Confounding
Section titled “Phenotypic Definition and Environmental Confounding”The precise definition and measurement of metabolic phenotypes, including deoxycarnitine levels, present challenges that can influence the interpretation of genetic associations. Inconsistent handling of confounding factors, such as lipid-lowering medication use, can introduce variability; while some studies meticulously excluded individuals on such therapies, others lacked this information or did not consider it.[2]This disparity means that observed genetic effects might be influenced by pharmacological interventions rather than solely by endogenous genetic variation, especially for metabolites like deoxycarnitine which are part of broader metabolic pathways. Furthermore, the practice of adjusting for covariates like age, gender, and disease status varied across cohorts, leading to different phenotypic residuals being used in genotype-phenotype association analyses and potentially masking or altering true genetic signals.[2]
Environmental factors and gene-environment interactions, though challenging to fully capture, are known to significantly influence complex traits and metabolic profiles. For instance, sex-based differences in genetic risk profiles for lipids have been observed, with some genes such as HMGCR and NCAN exhibiting significantly different effect sizes between males and females, reflecting known epidemiological and clinical variations. [8]Such sex-specific effects could similarly modulate genetic associations with deoxycarnitine, yet many studies do not explicitly address these potential differences. The complex interplay between genetic predisposition, diet, lifestyle, and other environmental exposures remains largely unexplored in the context of many metabolites, representing a crucial knowledge gap that, if unaddressed, limits a comprehensive understanding of the genetic regulation of deoxycarnitine levels.
Future Research Directions and Knowledge Gaps
Section titled “Future Research Directions and Knowledge Gaps”Despite significant advances, current research highlights several remaining knowledge gaps and areas for future investigation concerning the genetic regulation of metabolites like deoxycarnitine. Many identified genetic associations represent correlations, and their functional mechanisms impacting metabolism often require further elucidation.[5]Comprehensive functional studies are essential to validate findings and to understand how specific genetic variants influence the expression, activity, or interaction of genes and proteins within metabolic pathways, ultimately leading to changes in deoxycarnitine levels.[5] The identification of novel sequence variants and the full spectrum of genetic contributions to complex traits necessitate even larger sample sizes and improved statistical power for comprehensive gene discovery. [2]
Moreover, the extent of missing heritability for complex metabolic traits suggests that current genetic models may not fully account for all genetic influences, implying that rare variants, structural variations, or more complex gene-gene and gene-environment interactions still await discovery. Further investigation is needed to explore the potential roles of neighboring genes and their interplay in lipid and overall metabolic regulation, which could indirectly affect deoxycarnitine.[8]Addressing these gaps will require integrating multi-omics data, employing advanced statistical methods, and conducting targeted functional experiments to move beyond associative findings towards a mechanistic understanding of deoxycarnitine metabolism.
Variants
Section titled “Variants”Genetic variations play a crucial role in influencing metabolic pathways and an individual’s predisposition to various traits, including the regulation of deoxycarnitine levels. Deoxycarnitine is a key precursor to L-carnitine, which is essential for fatty acid transport into mitochondria for energy production. Variants within or near genes involved in carnitine synthesis, nutrient transport, and broader metabolic regulation can impact the efficiency of these processes, thereby affecting circulating deoxycarnitine and overall metabolic health.
The genes BBOX1 and BBOX1-AS1are directly implicated in carnitine metabolism.BBOX1encodes gamma-butyrobetaine dioxygenase, a pivotal enzyme responsible for the final step in L-carnitine biosynthesis.BBOX1-AS1 is an antisense RNA that can influence the expression and activity of BBOX1. Variants such as rs201184146 , rs78470357 , rs891532338 , and rs147289644 , located within or near these genes, may alter the efficiency of carnitine production.[9]Such genetic changes can lead to variations in deoxycarnitine levels and subsequently impact fatty acid oxidation, energy metabolism, and lipid profiles, contributing to individual differences in metabolic health.[6]
Other solute carrier genes, SLC6A13 and SLC16A9, are involved in transporting specific molecules across cell membranes, which is fundamental to cellular function and metabolism. SLC6A13encodes a GABA transporter, primarily regulating neurotransmitter levels, and its variants likers10774021 , rs11062102 , and rs11613331 may affect neuronal signaling and indirectly influence systemic metabolic states. SLC16A9 codes for a monocarboxylate transporter, which facilitates the movement of various monocarboxylates crucial for energy metabolism and waste removal. [1] Variations such as rs1171614 , rs1171617 , and rs1171615 could alter the transport efficiency of these substrates, leading to broader metabolic disturbances that might affect carnitine pathways and lipid homeostasis.[4]
A diverse group of genes, including SLC25A45, ZNF28, LUZP2, and LINC02938, also harbor variants that can influence metabolic processes. SLC25A45 encodes a mitochondrial solute carrier, with variants like rs78829599 and rs34400381 potentially affecting the transport of molecules into mitochondria, thereby impacting mitochondrial function and energy production. ZNF28 (zinc finger protein 28) is a transcription factor, and its variant rs6509694 may modulate the expression of other genes involved in cellular regulation. Similarly, LUZP2(leucine zipper protein 2) with variantrs1268699195 , and LINC02938 (long intergenic non-coding RNA) with variant rs191167509 , can influence gene expression and cellular pathways. [10]While their direct impact on deoxycarnitine is complex and often indirect, these genetic variations contribute to the intricate network of metabolic regulation, potentially affecting the balance of circulating metabolites, including those related to carnitine and fatty acid metabolism.[11]
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs10774021 rs11062102 rs11613331 | SLC6A13 | chronic kidney disease, serum creatinine amount serum creatinine amount, glomerular filtration rate BMI-adjusted waist circumference 1-methylimidazoleacetate measurement deoxycarnitine measurement |
| rs1171614 rs1171617 rs1171615 | SLC16A9 | urate measurement serum metabolite level body height gout appendicular lean mass |
| rs201184146 | BBOX1, BBOX1-AS1 | deoxycarnitine measurement |
| rs78470357 | BBOX1-AS1 | deoxycarnitine measurement |
| rs78829599 rs34400381 | SLC25A45 | serum creatinine amount glomerular filtration rate deoxycarnitine measurement |
| rs891532338 | BBOX1-AS1, BBOX1 | deoxycarnitine measurement |
| rs147289644 | BBOX1-AS1, BBOX1 | deoxycarnitine measurement |
| rs6509694 | ZNF28 | deoxycarnitine measurement |
| rs1268699195 | LUZP2 | deoxycarnitine measurement |
| rs191167509 | LINC02938 | deoxycarnitine measurement |
Biological Background
Section titled “Biological Background”Metabolomic Insights into Lipid and Cholesterol Homeostasis
Section titled “Metabolomic Insights into Lipid and Cholesterol Homeostasis”Metabolomics is a rapidly advancing field dedicated to the comprehensive measurement of endogenous metabolites within a cell or body fluid, providing a functional readout of the physiological state of the human body. [1] These studies often focus on the homeostasis of key lipids, carbohydrates, or amino acids, as genetic variants influencing these pathways can significantly impact health. [1] Within this framework, lipid metabolism, including the synthesis and regulation of cholesterol, is a critical biological process involving numerous enzymes and signaling pathways. For instance, the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is a central player in the mevalonate pathway, which is responsible for cellular cholesterol synthesis [12]. [3]
Beyond synthesis, other key biomolecules contribute to the complex regulation of lipid concentrations and transport. Lecithin:cholesterol acyltransferase (LCAT), for example, is an enzyme involved in cholesterol esterification, a process crucial for the maturation of high-density lipoprotein (HDL) and reverse cholesterol transport.[13]Furthermore, apolipoproteins like Apolipoprotein B (APOB) are essential structural components of lipoproteins, which facilitate the transport of lipids, including cholesterol and triglycerides, throughout the bloodstream. [14] Disruptions in the functions of these proteins or the pathways they govern can lead to imbalances in lipid profiles, affecting overall metabolic health.
Genetic Regulation of Lipid Metabolism and Gene Expression
Section titled “Genetic Regulation of Lipid Metabolism and Gene Expression”Genetic variants play a substantial role in modulating an individual’s lipid profile and overall metabolic phenotype. Genome-wide association studies (GWAS) have identified numerous genetic loci and single nucleotide polymorphisms (SNPs) that associate with variations in circulating lipid concentrations, such as low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides.[6] These genetic insights highlight how inherited factors can influence the efficiency of metabolic pathways and the levels of various metabolites in the body. For example, common SNPs in the HMGCR gene have been found to influence LDL-C levels. [3]
One important mechanism through which genetic variants can exert their effects is alternative splicing, a process where a single gene can produce multiple protein isoforms with potentially different functions. [15] Specific SNPs can affect regulatory elements within gene sequences, leading to altered splicing patterns. For instance, SNPs in HMGCR, such as rs3846662 , have been shown to influence the alternative splicing of exon 13, producing a variant HMGCR mRNA that lacks this exon. [3] This genetic modulation of gene expression patterns can directly impact the quantity and functionality of key enzymes involved in metabolic processes.
Molecular and Cellular Impact of HMGCR Splicing
Section titled “Molecular and Cellular Impact of HMGCR Splicing”The alternative splicing of HMGCR to produce a Δexon13 variant has significant molecular and cellular consequences for cholesterol metabolism. Exon 13 encodes a crucial part of the HMGCR catalytic domain, including sequences vital for enzyme dimerization and a residue (E559) proposed to participate directly in the reduction of HMG-CoA. [3] The deletion of this exon can therefore impair the enzyme’s stability and catalytic activity, potentially leading to faster degradation of the protein. [3] In experimental cellular models, the Δexon13 variant of HMGCR has been observed to be non-functional, unable to restore cell growth in the absence of mevalonate, which is a downstream product of the HMGCR pathway. [3]
A decrease in functional HMGCR activity due to alternative splicing would lead to reduced cellular cholesterol synthesis. [3] To maintain intracellular cholesterol homeostasis, cells would then increase their uptake of cholesterol from the plasma via the LDL-receptor pathway. [3] This compensatory response illustrates a regulatory network where genetic variations influencing splicing can alter enzyme function, thereby triggering broader cellular signaling pathways to maintain metabolic balance. Such mechanisms highlight the intricate interplay between genetic predisposition, molecular processes, and cellular functions in regulating metabolite levels.
Pathophysiological Relevance and Systemic Consequences
Section titled “Pathophysiological Relevance and Systemic Consequences”The genetic and molecular mechanisms influencing lipid and cholesterol metabolism have profound pathophysiological implications, particularly for cardiovascular health. Alterations in LDL-C levels, often influenced by genetic variants in genes likeHMGCR, are well-established risk factors for conditions such as dyslipidemia and coronary artery disease.[6] The systemic consequences of these genetic influences are evident in population studies where specific haplotypes associated with lower LDL-C levels are linked to alleles that cause higher levels of the non-functional Δexon13 HMGCR mRNA. [3]
Furthermore, these biological insights inform pharmacological interventions, such as statin therapy, which targets HMGCR activity to lower cholesterol. [3] Genetic variations, including those affecting alternative splicing, can modulate an individual’s response to statin treatment, suggesting a potential for pharmacogenomic applications. [3] Beyond cholesterol, other lipid-related genes like the fatty acid desaturase genes (FADS1 and FADS2) influence the composition of polyunsaturated fatty acids, further demonstrating the broad tissue and organ-level effects of genetic variations on systemic lipid metabolism and overall health. [16]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Metabolic Integration with Lipid and Energy Homeostasis
Section titled “Metabolic Integration with Lipid and Energy Homeostasis”Deoxycarnitine, as a component of the human metabolome, is intrinsically linked to broader metabolic pathways, particularly those governing lipid and energy homeostasis. Metabolomics studies aim to comprehensively measure endogenous metabolites in body fluids, providing a functional readout of the physiological state.[1]In this context, deoxycarnitine levels reflect the dynamic balance within lipid metabolism, where carnitine and its derivatives are crucial for the transport of fatty acids into mitochondria for beta-oxidation and energy production. Variations in deoxycarnitine levels can therefore serve as indicators of altered fatty acid handling or overall energy status, contributing to the understanding of lipid, carbohydrate, and amino acid homeostasis.[1]
Genetic Regulation of Metabolite Profiles
Section titled “Genetic Regulation of Metabolite Profiles”Genetic variants play a significant role in influencing the levels of various metabolites, including deoxycarnitine, by modulating the activity of enzymes and transporters involved in metabolic pathways. Genome-wide association studies (GWAS) have identified specific genetic loci associated with changes in metabolite profiles in human serum.[1]For instance, common single nucleotide polymorphisms (SNPs) can affect alternative splicing of genes likeHMGCR, which encodes 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key enzyme in cholesterol biosynthesis. [3]Such genetic influences on metabolic enzymes can alter flux through pathways related to lipid synthesis and breakdown, thereby indirectly impacting the pool of carnitine-related metabolites like deoxycarnitine. Similarly, variants in gene clusters such asFADS1 and FADS2, which are involved in fatty acid desaturation, are associated with the composition of polyunsaturated fatty acids [16]further illustrating the genetic control over lipid metabolism that could influence deoxycarnitine levels.
Regulatory Mechanisms in Metabolic Control
Section titled “Regulatory Mechanisms in Metabolic Control”The pathways associated with deoxycarnitine, and indeed all metabolic processes, are subject to intricate regulatory mechanisms that ensure metabolic balance. These mechanisms include gene regulation, protein modification, and allosteric control, which collectively govern enzyme activity and pathway flux. While specific regulatory details for deoxycarnitine are not explicitly provided, the impact of genetic variants on alternative splicing, as observed forHMGCR, demonstrates a crucial post-transcriptional regulatory layer that can alter protein structure and function, directly affecting metabolic output. [3]This highlights how genetic predisposition can fine-tune the efficiency and responsiveness of metabolic enzymes, thereby influencing the dynamic concentrations of metabolites like deoxycarnitine within the systemic network.
Deoxycarnitine within Systemic Metabolic Networks
Section titled “Deoxycarnitine within Systemic Metabolic Networks”Deoxycarnitine exists not in isolation, but as an integral part of a complex and interconnected metabolic network, where pathway crosstalk and hierarchical regulation contribute to emergent physiological properties. Metabolomic analyses reveal that changes in one metabolite can ripple through the entire system, indicating extensive network interactions.[1] For example, while SLC2A9 (encoding GLUT9) is known to influence uric acid concentrations and transport[17]this demonstrates how specific transporters regulate metabolite levels, and similar principles apply to other metabolic intermediates. The observed levels of deoxycarnitine therefore represent an emergent property of the integrated activities of various lipid, carbohydrate, and amino acid pathways, reflecting the overall metabolic state and its systemic regulation.
Clinical Relevance and Disease Associations
Section titled “Clinical Relevance and Disease Associations”The dysregulation of pathways involving metabolites like deoxycarnitine can have significant clinical implications, contributing to various disease states, particularly those related to metabolic disorders. Genome-wide association studies have linked genetic variants to metabolic traits, including lipid concentrations and the risk of coronary artery disease.[2]As deoxycarnitine is identified within metabolomic profiles associated with genetic variants, its aberrant levels could signify underlying pathway dysregulation relevant to conditions such as dyslipidemia or cardiovascular disease.[1]Understanding the mechanisms that govern deoxycarnitine levels could therefore offer insights into disease pathophysiology, potentially identifying novel biomarkers or therapeutic targets for metabolic health.
Clinical Relevance
Section titled “Clinical Relevance”Emerging Role in Biomarker Discovery and Genetic Associations
Section titled “Emerging Role in Biomarker Discovery and Genetic Associations”Deoxycarnitine has been identified as a select biomarker trait, which was included in genome-wide association studies (GWAS) conducted within the Framingham Heart Study.[5]Such large-scale genetic investigations are instrumental in exploring the genetic basis of various physiological traits and their potential links to health outcomes. The investigation of biomarkers like deoxycarnitine within comprehensive cohorts contributes to the broader understanding necessary for developing tools for risk stratification, predicting disease progression, and informing personalized medicine approaches, although specific clinical applications for deoxycarnitine require further validation in diverse populations.[5]
References
Section titled “References”[1] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, e1000282.
[2] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 40, no. 1, 2008, pp. 189–197.
[3] Burkhardt, R., et al. “Common SNPs in HMGCR in Micronesians and Whites Associated with LDL-Cholesterol Levels Affect Alternative Splicing of Exon13.” Arterioscler Thromb Vasc Biol, vol. 28, no. 12, 2008, pp. 2221-2228.
[4] Wallace C, et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.”Am J Hum Genet, vol. 82, no. 1, 2008, pp. 139–149.
[5] Benjamin EJ, et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, 2007, p. S1. PMID: 17903293.
[6] Willer CJ, et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 1, 2008, pp. 181–188.
[7] Hwang, S. J. et al. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Med Genet, vol. 8, 2007, p. 58.
[8] Aulchenko, Y. S. et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nat Genet, vol. 40, no. 11, 2008, pp. 1292-301.
[9] Kathiresan, S. et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 41, no. 1, 2009, pp. 56-65.
[10] Sabatti C, et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nat Genet, vol. 40, no. 12, 2008, pp. 1396–1406.
[11] Saxena R, et al. “Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.”Science, vol. 316, no. 5829, 2007, pp. 1331–1336.
[12] Goldstein, Joseph L., and Michael S. Brown. “Regulation of the mevalonate pathway.” Nature, vol. 343, no. 6257, 1990, pp. 425-430.
[13] Kuivenhoven, Jan A., et al. “The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.” Journal of Lipid Research, vol. 38, no. 2, 1997, pp. 191-205.
[14] Khoo, Brenda, et al. “Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.” BMC Molecular Biology, vol. 8, no. 1, 2007, p. 3.
[15] Matlin, Andrew J., et al. “Understanding alternative splicing: towards a cellular code.” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, 2005, pp. 386-398.
[16] Schaeffer, L., et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet, 2006.
[17] Vitart, V., et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.”Nat Genet, 2008.